Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 7—July 2021
Dispatch

Pneumococcal Disease Outbreak at a State Prison, Alabama, USA, September 1–October 10, 20181

Guillermo V. SanchezComments to Author , Constance L. Bourne, Sherri L. Davidson, Mark Ellis, Leora R. Feldstein, Katherine Fay, Nicole E. Brown, Evelyn F. Geeter, Lytasha L. Foster, Charlotte Gilmore, Mary G. McIntyre, Burnestine Taylor, Srinivasan Velusamy, Sopio Chochua, and Almea M. Matanock
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (G.V. Sanchez, L.R. Feldstein, K. Fay, N.E. Brown, S. Velusamy, S. Chochua, A.M. Matanock); Alabama Department of Public Health, Montgomery, Alabama, USA (G.V. Sanchez, C.L. Bourne, S.L. Davidson, M. Ellis, E.F. Geeter, L.L. Foster, C. Gilmore, M.G. McIntyre, B. Taylor)

Main Article

Table 2

Administration of pneumococcal polysaccharide vaccine and antibiotic prophylaxis to reduce Streptococcus pneumoniae transmission in prison inmates during a pneumococcal disease outbreak, Alabama, USA, September 29–October 10, 2018*

Prophylaxis type Status No. (%)
Inmates, n = 264† Medical staff, n = 52 Prison employees, n = 72
PPSV23 vaccine
Received 206 (78) 32 (62) 62 (86)
Declined 58 (22) 18 (35) 8 (11)
Absent or unknown
0
2 (4)
2 (3)
Dose 1: azithromycin 500 mg‡
Received 232 (88) 11 (21) 70 (97)
Declined 15 (6) 6 (12) 0
Absent or unknown
17 (6)
35 (67)
2 (3)
Dose 2: azithromycin 1000 mg Received 246 (93) 35 (67) 46(64)
Declined 18 (7) 16 (31) 4 (6)
Absent or unknown 0 1 (2) 22 (31)

*Because of rounding, all cells might not sum to 100%. PPSV23, 23-valent pneumococcal polysaccharide vaccine. †Inmates assigned to dormitory X (n = 255) or living in dormitory X without an assignment (n = 9) were offered prophylaxis. Not all inmates lived or slept in the dorm to which they were assigned. ‡Initial antibiotic prophylaxis dosing was chosen by the Alabama Department of Corrections as 500 mg offered on September 29 and a planned second dose of 500 mg 1 week later. This dose would have provided less antibiotic coverage than previous outbreak regimens. Based on Alabama Department of Health recommendations, a higher, single dose of azithromycin (1,000 mg) was offered during October 3–October 10.

Main Article

1Preliminary results from this study were presented at the Centers for Disease Control and Prevention 2019 Epidemic Intelligence Service conference, April 29–May 2, 2019, Atlanta, Georgia, USA.

Page created: April 27, 2021
Page updated: June 17, 2021
Page reviewed: June 17, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external